<?xml version="1.0" encoding="UTF-8"?>
<p id="Par21">Persistent high-risk human papillomavirus (HR-HPV) infection is necessary for the progression of cervical cancer [
 <xref ref-type="bibr" rid="CR1">1</xref>, 
 <xref ref-type="bibr" rid="CR2">2</xref>]. The development of prophylactic HPV vaccines has led a momentous positive impact on cervical cancer prevention and control. High efficacy of HPV vaccine has been demonstrated against cervical intraepithelial neoplasia (CIN) grade II/III among women who are HPV-naive at vaccination in multiple studies [
 <xref ref-type="bibr" rid="CR3">3</xref>, 
 <xref ref-type="bibr" rid="CR4">4</xref>]. However, the impact of prophylactic vaccine on women who have been previously treated for CIN has not been fully understood.
</p>
